Dr. Tymianski is a cerebrovascular neurosurgeon-scientist. He is a Professor of Surgery at the University of Toronto and a member and past head of the Division of Neurosurgery at the University Health Network, the largest division of Neurosurgery in Canada.
He is also a Senior Scientist in the Krembil Institute and a Professor of Neurosurgery at the University of Toronto. He is the Harold and Esther Halpern Chair in Neurosurgical Stroke Research and a Canada Research Chair (Tier 1) in Translational Stroke Research.
His research focuses on understanding of the cellular and molecular mechanisms of stroke. His most advanced contribution relates to the development of PSD95 inhibitors- drugs that lessen stroke damage. NA-1, the lead PSD95 inhibitor, has been translated by Dr. Tymianski and his team from the discovery of the molecule, through animal testing, and now to Phase 3 clinical trials.
He participates in a multi-disciplinary team that treats patients with the most challenging cerebrovascular problems, and has a practice consisting of the entire range of neurovascular surgery. Among his surgical interests are the development of methods for minimally-invasive surgery for brain aneurysms, cerebral revascularization, and brain arteriovenous malformations. He has also introduced the concept of outpatient aneurysm surgery.
Dr. Tymianski is the recipient of multiple grants and awards. In 2016 he was appointed to the Order of Canada, the cornerstone of the Canadian Honours System, that recognizes outstanding achievement, dedication to the community and service to the nation.
